Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and substance for keeping fibrinogen activity in thermal treatment

A fibrinogen and protein activity technology, applied in the field of protein activity maintenance, can solve the problem of inactivation of non-lipid envelopes

Active Publication Date: 2009-09-30
SHANGHAI RAAS BLOOD PRODUCTS CO LTD
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the S / D method cannot inactivate the non-lipid envelope, and the coagulation factor products treated only with the S / D method still have the possibility of spreading non-lipid envelope viruses such as hepatitis A and B19

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and substance for keeping fibrinogen activity in thermal treatment
  • Method and substance for keeping fibrinogen activity in thermal treatment
  • Method and substance for keeping fibrinogen activity in thermal treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Preparation of fibrinogen composition①

[0113] Adjust the pH of human plasma to 5.0-9.0, add ethanol and centrifuge to obtain a precipitate rich in fibrinogen.

[0114] Dissolve the precipitate in sodium citrate-Tris buffer, pH 6.0-8.0, filter to remove insoluble particles, then add Tween 80 (Tween80) and tributyl phosphate (TNBP) to the solution to the final concentration of Tween80 TNBP is 1.0%, TNBP is 0.3%, the temperature of the solution is adjusted to 24-26° C., and it is incubated for at least 6 hours to inactivate the lipid-enveloped virus.

[0115] After S / D virus inactivation treatment, dilute with sodium citrate-Tris buffer solution, pH 6.0-8.0, cool down the solution, add ethanol and centrifuge to obtain a precipitate.

[0116] The precipitate was redissolved in sodium citrate-Tris buffer, the pH was 6.0-8.0, filtered, the solution was cooled down, and ethanol was added to centrifuge to obtain a purified precipitate.

[0117] Dissolve one part of this pre...

Embodiment 2

[0120] Preparation of fibrinogen composition②

[0121] Dissolve one part of this precipitate in three parts at 25°C in sodium citrate-hydrochloric acid buffer solution, pH 6.0-8.0, and the resulting solution contains 2.0% fibrinogen, 5 mmol / L sodium citrate, L- Arginine hydrochloride 5g / L, glycine 5g / L.

Embodiment 3

[0123] Preparation of fibrinogen composition③

[0124] Dissolve one part of this precipitate in three parts at 25°C in sodium citrate-hydrochloric acid buffer solution, pH6.0-8.0, and the resulting solution contains 5.0% fibrinogen, sodium citrate 100mmol / L, L- Arginine hydrochloride 100g / L, glycine 100g / L.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method and a substance for still keeping protein activity for a fibrinogen after two steps of virus-inactivating treatments by an S / D method and dry heat virus inactivation.

Description

technical field [0001] The present invention relates to the maintenance of protein activity, in particular to the material and method for making fibrinogen maintain protein activity during dry heat inactivation virus treatment. Background technique [0002] Human fibrinogen, coagulation factor I, is one of the main components of plasma proteins, with a molecular weight of about 340,000. Fibrinogen can form fibrin under the action of thrombin, and fibrin then forms a stable fibrin thrombus together with platelets. Clinically, fibrinogen can be supplemented through intravenous injection alone, and fibrinogen can also be used together with thrombin for emergency hemostasis and wound adhesion. [0003] With the development of science and technology, the potential risks of blood products have been paid more attention. The 2005 edition of the "Chinese Pharmacopoeia" was promulgated and implemented, and it has been clearly stated that "approved methods should be used to remove an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K1/00C07K14/75
Inventor 黄凯何秋沈积慧胡维兵施炜
Owner SHANGHAI RAAS BLOOD PRODUCTS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com